Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | F11 | P03951 | 3/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.41 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204223 | 0.88 | STIM1 (0.53) | KMT2AMAPTPTGS2ALDH1A1HPGD | |
| SCHEMBL2206505 | 0.87 | KMT2A (0.44) | KMT2AMEN1ERN1PTGS2ALDH1A1 | |
| SCHEMBL2203624 | 0.85 | TP53 (0.48) | KMT2APTGS2TP53EPHX2STIM1 | |
| SCHEMBL2206805 | 0.85 | NOTUM (0.46) | KMT2AMEN1F11KLKB1 | |
| SCHEMBL4331296 | 0.83 | F2 (0.43) | KMT2AMEN1F11USP2ALDH1A1 | |
| SCHEMBL358511 | 0.83 | SRD5A2 (0.48) | KMT2AMEN1F11 | |
| SCHEMBL2205182 | 0.81 | RXFP1 (0.50) | KMT2AERN1PTGS2ALDH1A1HPGD | |
| SCHEMBL2204512 | 0.81 | GAA (0.57) | KMT2AMEN1MAPTALDH1A1TP53 | |
| SCHEMBL356937 | 0.81 | NOTUM (0.43) | KMT2AMEN1F11KLKB1 | |
| SCHEMBL2410383 | 0.81 | ALDH1A1 (0.57) | KMT2AMEN1USP2ERN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205573-B1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | claimed |
| EP-2205573-B1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-7981914-B2 | Tetrazole-substituted aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090093523-A1 | Tetrazole-substituted aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093523-A1 | Tetrazole-substituted aryl amide derivatives and uses thereof | AR, NAT1, TBXA2R | KMT2A 1756/4885MEN1 1261/4885MAPT 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.